Indore facility OAI classification
Indore facility received OAI from US FDA; corrective measures are ongoing but may delay US approvals.
CIPLA / Q2-FY24 / risks
Keep the risk register visible.
Cipla · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Albuterol market share volatility
Albuterol share is dependent on which variant the market buys; recovery to prior highs is not fully in Cipla's control.
Revlimid volume uncertainty post-12-month period
Analyst questioned Revlimid volume trajectory after the initial 12-month period; management gave no specific guidance.